Industry Briefing
A single destination for timely, editor-curated robotics news from around the world.
NVIDIA BioNeMo Agent Toolkit Brings Accelerated AI to Life Sciences Researchers in Claude Science
NVIDIA is at the forefront of a transformative shift in the life sciences sector, leveraging over a decade of expertise in developing a comprehensive GPU-accelerated computing stack. This stack includes hardware, frameworks, libraries, models, microservices, and specialized tools designed to enhance computational capabilities in biological research and healthcare. The company's advancements are aimed at addressing the growing demand for sophisticated data analysis and processing in life sciences, which has increasingly relied on computational power to drive innovation and discovery. As of October 2023, NVIDIA's initiatives are set to revolutionize how researchers and healthcare professionals utilize technology, ultimately improving outcomes in various applications from drug discovery to personalized medicine.
"BioGeometry" secures hundreds of millions in strategic funding to create a "microscopic world model" in life sciences.
AI-native biotechnology company BaiAo Geometry has successfully secured several hundred million yuan in strategic financing, with investments led by the Shanghai Biomedical Innovation Transformation Fund, Guoke Investment, Dacheng Wisdom, and Xinglian Capital, alongside follow-on investments from GaoRong Capital and the Index AI Industry Innovation Fund. The funds will primarily support the ongoing development of their life sciences micro-world model, GeoFlow, and the advancement of their proprietary drug pipeline. Artificial intelligence is rapidly evolving along two main trajectories: digital AI, represented by large language and multimodal models, and physical AI, exemplified by autonomous vehicles and humanoid robots. Life AI is emerging as a promising frontier, a sentiment echoed by leading global investors and scientists. BaiAo Geometry's GeoFlow model, launched in 2024, aims to understand and design molecular interactions at an atomic level, enabling the creation of novel molecules that have never existed in nature. The company has iterated GeoFlow multiple times, achieving significant advancements in protein structure prediction and de novo design capabilities. By applying Test-Time Scaling technology, BaiAo Geometry enhances the success rate of protein designs without the need for extensive retraining. This innovation allows for the rapid generation and optimization of high-affinity binding molecules, significantly reducing the time and cost associated with traditional drug discovery processes. BaiAo Geometry has established over 20 business development collaborations with domestic and international pharmaceutical companies, focusing on high-specificity antibody design and vaccine development. The company is currently working on the next iteration of GeoFlow, which aims to expand modeling from individual molecules to entire molecular systems, further revolutionizing drug development in the biotechnology sector.
OpenAI releases life sciences AI "GPT-Rosalind" for bio-defense, raising concerns over dual-use risks.
OpenAI has launched the "Rosalind Biodefense" program, utilizing its frontier reasoning model, GPT-Rosalind, specifically designed for life sciences research. Announced recently, this initiative focuses on detecting biological threats for defense purposes. The program will provide approved developers, U.S. government agencies, and allied partner organizations with free access to its API, aiming to enhance biodefense capabilities.
NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery
NVIDIA has unveiled a significant expansion of its BioNeMo™ platform, an open development system designed to facilitate lab-in-the-loop workflows aimed at advancing AI-driven biology and drug discovery. This announcement was made today, reflecting NVIDIA's commitment to enhancing research capabilities in the life sciences sector. By integrating AI technologies with biological research, the platform aims to streamline the drug discovery process, allowing scientists to leverage advanced computational tools to accelerate their findings. The expansion is expected to foster collaboration among researchers and institutions, ultimately driving innovation in the field of biotechnology.
Robotics needs a service framework.
RSF defines a common language for robot service capability, lifecycle operations, certification pathways, and service-provider networks.
Join the RobotToday community on LinkedIn
Daily robotics news, in-depth analysis, conference highlights, and discussions with professionals worldwide.
